J Biol Chem, Vol. 273, Issue 26, 16391-16399, June 26, 1998
Chicken Ovalbumin Upstream Promoter-Transcription Factor
(COUP-TF) Modulates Expression of the Purkinje Cell Protein-2
Gene
A POTENTIAL ROLE FOR COUP-TF IN REPRESSING PREMATURE THYROID
HORMONE ACTION IN THE DEVELOPING BRAIN*
Grant W.
Anderson,
Ruby J.
Larson,
Daniel R.
Oas,
Charles R.
Sandhofer,
Harold L.
Schwartz,
Cary N.
Mariash, and
Jack H.
Oppenheimer
From the Thyroid Research Unit, Division of Endocrinology and
Diabetes, Department of Medicine and Department of Cell Biology and
Neuroanatomy, University of Minnesota,
Minneapolis, Minnesota 55455
 |
ABSTRACT |
The cerebellar Purkinje cell-specific PCP-2 gene
is transcriptionally activated by thyroid hormone during the 2nd and
3rd weeks of postnatal life in the rat. In contrast, thyroid hormone has no detectable effects on PCP-2 expression in the fetal rat. We now
present data that suggest that the orphan nuclear receptor chicken
ovalbumin upstream promoter-transcription factor (COUP-TF) represses
triiodothyronine (T3)-dependent transcriptional activation of PCP-2 in the immature Purkinje cell. Gel shift assays show that the
PCP-2 A1TRE and adjoining sequences (
295/
199 region) bind to rat
and mouse brain nucleoproteins in a developmentally regulated fashion
and that one of these nucleoproteins could be the orphan nucleoprotein
COUP-TF. In support of this hypothesis, in vitro translated
COUP-TF binds to the
295/
199 region and COUP-TF represses
T3-dependent activation of the PCP-2 promoter in transient
transfection analyses. Finally, immunohistochemical studies reveal that
COUP-TF is specifically expressed in the immature fetal and early
neonatal Purkinje cell and that this expression diminishes coincident
with thyroid hormone induction of PCP-2 expression. Our findings are
consistent with the hypothesis that the presence or absence of
inhibitory proteins bound to the thyroid hormone response element of
T3-responsive genes governs the responsivity of these genes to thyroid
hormone during brain development.
 |
INTRODUCTION |
Thyroid hormone plays an important role in mammalian cerebellar
development (1). Thyroid hormone affects development of a variety of
cerebellar cells including the Purkinje cell (2). Purkinje cells are
generated by embryonic (E)1
day 15 in the fetal rat and migrate to the cerebellar anlage before
birth (3). Maturation of these cells is delayed until shortly after
birth and is completed during the first few weeks of neonatal life (4).
Migration of immature Purkinje cells and formation of the fetal
cerebellar anlage appear to be unaffected by the presence or absence of
thyroid hormone (5). In contrast, however, absence of thyroid hormone
during the first 2 weeks after birth leads to irreversible reductions
in Purkinje cell dendritic growth (2, 6).
We have chosen the Purkinje cell-specific gene Purkinje cell protein-2
(PCP-2) as a model gene with which to study thyroid hormone effects on
the developing Purkinje cell. Expression of PCP-2, like development of
the Purkinje cell, is only transiently responsive to thyroid hormone
stimulation (7, 8). PCP-2 expression is stimulated by thyroid hormone
during the 2nd and 3rd weeks of postnatal life in the mouse and rat.
Conversely, the gene is refractory to thyroid hormone stimulation in
the fetus and early neonate and also in the adult. Other genes,
including the cerebellar specific calbindin and
myoinositol-1,4,5-triphosphate receptor genes and the
oligodendrocyte-specific myelin basic protein gene respond to thyroid
hormone in a similar, transient fashion during cerebellar development
(7). Studies from our laboratory have further revealed that the PCP-2
promoter can be directly regulated by T3 (7, 9). We have identified two
thyroid hormone response elements (TREs) within the PCP-2 regulatory
region, one situated in the 5' upstream region (A1TRE,
295/
268) and
a second apparently nonfunctional TRE in the first intron (10, 11).
Immature fetal and early neonatal Purkinje cells express the
isoform of the thyroid hormone receptor (12). Additionally, T3 is
present in the late gestational and early neonatal rat brain (13).
Nevertheless, the PCP-2 gene in the immature Purkinje cell is
refractory to thyroid hormone stimulation (5, 7, 8). We have recently
examined two potential mechanisms that could have accounted for the
observed T3 nonresponsivity of the PCP-2 gene in the fetal rat: 1) that
T3-dependent activation of PCP-2 specifically requires the
1 isoform of the thyroid hormone receptor; and 2) that fetal brain
T3 levels are insufficient for activation of the PCP-2 gene.
Since expression of the thyroid hormone receptor isoform
1 in the
brain immediately precedes T3-dependent activation of the PCP-2 gene (14), our laboratory had previously raised the possibility that the TR
1 isoform is specifically required for
T3-dependent activation of the PCP-2 gene (7). Sandhofer
et al. (8), however, have recently shown that the ontogenic
pattern of PCP-2 expression in TR
null mice (15) is
indistinguishable from that of wild type pups, a finding which
effectively excludes the possibility that the TR
gene is essential
for appropriate developmental expression of the PCP-2 gene.
Additionally, Forrest et al. (15) have not detected
deficiencies in the cerebellar development of these mice. Thus, a lack
of TR
1 expression cannot account for PCP-2 T3 nonresponsivity in the
immature Purkinje cell.
Schwartz et al. (5) have recently determined that inadequate
levels of brain T3 also cannot account for PCP-2 T3 nonresponsivity in
the immature fetal Purkinje cell. The fetal thyroid begins secreting
thyroid hormone on embryonic day 17 in the rat (16). Brain T3 levels
rise approximately 10-fold from this stage of embryogenesis until birth
(13). After birth, brain T3 levels continue to increase rapidly and
reach adult normal levels by postnatal day 2 (see below). Although T3
is clearly present in the late gestational and early neonatal rat
brain, hypothyroidism does not measurably affect PCP-2 expression until
approximately 1 week after birth (7, 8). A potential explanation for
this T3 nonresponsivity is that T3 levels in the late gestational and early neonatal rat brain are insufficient for T3-dependent
activation of PCP-2 expression. Schwartz et al. (5),
however, found that the PCP-2 gene remains unresponsive to T3
stimulation in the late gestational rat fetus even if fetal brain T3
levels are artificially boosted to adult normal levels. Thus, low brain
T3 levels do not account for PCP-2 T3 nonresponsivity during late
gestational cerebellar development.
We have recently demonstrated that thyroid hormone signaling can be
inhibited by trans-acting factors that bind to specific cis-elements
within the regulatory regions of thyroid hormone responsive genes (9).
We observed that cis-elements within the PCP-2 upstream regulatory
region inhibit T3-dependent activation of the PCP-2
promoter in transient transfection assays. These cis-elements
(
267/
199 region) are located immediately 3' to the PCP-2 TRE
(
295/
268 region). Thyroid hormone signaling can also be inhibited
by trans-acting factors that compete with thyroid hormone receptors for
binding to thyroid hormone response elements (17-20).
We have recently found that developmentally regulated rat brain nuclear
proteins bind to the
295/
199 region of the PCP-2 gene (9).
Nucleoproteins harvested from both late gestational or adult rats bound
to the
295/
199 region (9). However, the binding activity diminished
strikingly in extracts prepared from adult rat brains. Competition
studies further revealed that both the A1TRE and the
267/
199 region
are required for binding activity (9). These findings are compatible
with a role for these nuclear proteins in repressing early PCP-2
expression.
We report here the identification of the orphan nuclear receptor
chicken ovalbumin upstream promoter-transcription factor (COUP-TF) as
one of the
295/
199 regions binding nucleoproteins, and we have
tested the possibility that COUP-TF could be an inhibitory trans-acting
factor involved in regulating PCP-2 expression during early Purkinje
cell development.
 |
EXPERIMENTAL PROCEDURES |
Animals and T3 Assay--
Pregnant female Swiss Webster mice and
Sprague-Dawley rats were purchased from Harlan (Madison, WI). Postnatal
day 0 corresponds to the 1st day after birth. Excess T3 levels in the
newborn rat brain were achieved by a single intraperitoneal injection
of thyroxine (T4, 100 µg of T4/100 g body weight) to the dam on day
21 of gestation. Such treatment has previously been demonstrated to
increase concentrations of T3 in the fetal brain (5, 21). Excess levels
of hormone were maintained postnatally by injecting pups with thyroxine
on a daily basis. Pups were injected daily with 1 µg of T4 through postnatal day 7. From P8 to P14 pups were injected daily with 2 µg of
T4 and with 4 µg of T4 from P15 to P21. Pups receiving this regimen
of treatment were born with levels of brain T3 greater than euthyroid
adult levels and remained elevated in these treated pups as they
continued to develop (data not shown). The concentration of brain T3
was assessed by the radioimmunoassay of Surks et al. (22).
Extraction of the iodothyronines from the brains was performed as
described by Morreale de Escobar et al. (16).
RNA Isolation and Northern Blot Analysis--
Total RNA was
extracted from the brains of individual rats (four per data point) by
the method of Chomcznski and Sacchi (23) and purified by repetitive
organic and salt washings (14). The relative mass of mRNA was
determined by Northern blot analysis as described previously (14).
Briefly, 10-µg aliquots of total RNA were electrophoresed on a 1%
agarose/formaldehyde gel and transferred to Magna nylon membrane (MSI,
Westboro, MA). Hybridization was done overnight at 42 °C with a
32P-labeled PCP-2 cDNA probe. The PCP-2 probe was a
gift of Dr. Harry Orr (University of Minnesota). Blots were washed and
subsequently exposed to phosphor screens (Molecular Dynamics,
Sunnyvale, CA) and scanned (PhosphorImager 445 SI, Molecular Dynamics,
Sunnyvale, CA). The images were quantified using ImageQuant 1.0 (Molecular Dynamics, Sunnyvale, CA). Samples were corrected for
variations in loading by calculating the ethidium bromide staining of
the 28 S and 18 S ribosomal RNA as described by Correa-Rotter
et al. (24).
Nuclear Extract Preparation and in Vitro Translation of
Receptors--
Mouse brain nuclear extracts were prepared from pooled
brains (3-12 animals) of mice of the indicated ages using a
modification of the Dignam procedure (10). Extractions were carried out
in the presence of protease inhibitors as described previously (9). Protein concentrations were determined using the Bradford assay (25).
In vitro translated receptors were prepared as described previously (10). Rat TR
1 cDNA was obtained from H. Towle
(University of Minnesota), mouse RXR
cDNA from K. Ozato
(National Institutes of Health), and mouse COUP-TFI from L. Jonk
(University of Groningen) (26).
Electrophoretic Mobility Shift Assay--
5'-Overhang ends of
HindIII-restricted
295/
199 region were labeled with
Klenow fragment (Life Technologies, Inc.) and
[
-32P]dCTP. Electrophoretic mobility shift assays were
carried out as described by Zou et al. (10) or, where
indicated, using the conditions described by Sagami et al.
(27). Competition electrophoretic mobility shift assays were carried
out as described by Zou et al. (10) except for the addition
of indicated amounts of competitor annealed oligonucleotide at the
initiation of the incubation period. Supershift analyses were carried
out by addition of 1 µl of specified antibodies to the reaction
mixture after the incubation period. The reaction mixture was
subsequently incubated for an additional 15 min at room temperature and
then loaded on the gel. Antibodies specific for COUP-TF (28) and TR
1
(Affinity Bioreagents Inc., Golden, CO) (29) have been described
previously. Anti-ROR antibody was kindly provided by Dr. Mitchell Lazar
(University of Pennsylvania).
Oligonucleotides and DNAs--
The PCP-2
295/
199 region used
as an electrophoretic mobility shift assay probe was isolated by
HindIII digestion of the A1(
267/
199)-MMTV construct (9).
The PCP-2
267/
199 region oligonucleotide was synthesized. The
sequences of all oligonucleotides used as probes or competitor
oligonucleotides (TRE half-sites are underlined and specific A1TRE
mutations are indicated by boldface type; the number in parentheses
corresponds to the reference where the nucleotide sequence was
obtained) are as follows: AGCTTGAATTCTTAGGGGTCAAAGGTCAAATGG COUP-RE (30);
AGGCCTTCTCAGGTCAGAGACCAGGAGA A1TRE
(10);
AGGCCTTCTCATTTCAGAGACCAGGAGA A1mI (10);
ATTCCTTCTCAGGTCAGAGACCAGGAGA
A1mII (10); AGGCCTTCTCAGGTCAGAGACCATTAGA
A1mIII (10);
ATTCCTTCTCAGGTCAGAGACCATTAGA A1mIV (10); ATTGCATTTCATTGAATTAGA 44/45 (11);
AGGTCAGCTGAGGTCA DR4;
TGACCTCGGCTGAGGTCA IR6;
TCGAGTTTTGGCTTGAAGCCAATATGAGC NF-1.
Transient Transfection Assays--
Neuro-2a cells were cultured
and transiently transfected using the calcium phosphate method as
described previously (9). Cells were cultured on 100-mm plates and
co-transfected with 5 µg of
PCP-2-CAT (9) and 5 µg of the
indicated receptor expression vectors together with 100 ng of RSV-Luc
and 10 µg of salmon testes DNA. Transfected cells were cultured in
the absence or presence of 100 nM T3 and harvested after
36 h. Luciferase activity was determined using an aliquot of the
cell extract and was used as a control in assessing transfection
efficiency (7). CAT assays were carried out as described previously
(9). Relative CAT activity is reported as CAT activity divided by the
transfection efficiency as determined by the luciferase assay. Each set
of DNAs was transfected in duplicate three times and reported as mean ± S.D. Fold induction is reported as the relative CAT
activity of transfected cells cultured in the presence of T3 divided by the relative CAT activity of transfected cells cultured in the absence
of T3. The DNAs used were A1
PCP-2-CAT (9), COUP-TFI pSG5 (26), pSG5,
and CDMTR
1 (10). The empty expression vector pSG5 was prepared by
removing the COUP-TFI cDNA from COUP-TFI pSG5 by EcoRI
restriction, removal of the insert, and religation of the vector.
Immunohistochemistry--
Fresh mouse brains were fixed in
neutral formalin for 1-4 h and then placed in 70% ethanol for at
least 4 h. The brains were embedded in Amerffin (American
Scientific Products, Minneapolis, MN). Sections of 8 µm each were
cut, floated onto a organosilane-treated slide in a 50 °C water
bath, and dried. Slides were subsequently heated at 60 °C for 30 min, deparaffinized in mixed xylenes twice for 10 min, and rehydrated
in graded ethanol (100, 80, and 70%). The tissue sections were then
placed in 0.01 M sodium citrate (pH 6.0), heated to near
boiling in a microwave for 10 min, and slowly cooled to room
temperature. The slides were then rinsed in water and soaked in
phosphate-buffered saline for 10 min. This procedure has been
previously used to aid in the immunohistochemical detection of antigens
in fixed tissues (31).
Calbindin expression was detected using the Histomouse kit from
Zymed Laboratories Inc. (South San Francisco, CA), and
COUP-TF expression was detected using Zymed's Histostain-SP kit. The
Histomouse kit is designed for detection of mouse antigens using mouse
monoclonal antibodies, and the Histostain-SP kit is designed for
detection of mouse antigens using rabbit primary antibody. The enzyme
used for generating a signal is horseradish peroxidase. The
peroxidase-stained tissue sections were not counterstained.
Anti-calbindin antibody (Sigma) was used at a 1:500 dilution;
anti-COUP-TF antibody was used at a 1:1000 dilution, and nonimmune
rabbit serum was used at a 1:1000 dilution.
 |
RESULTS |
Premature Elevations of Brain T3 Levels Do Not Result in
Acceleration of PCP-2 Gene Expression in the Early Rat
Neonate--
Previous studies have shown that PCP-2 T3 nonresponsivity
in the fetal rat is not due to insufficient levels of brain T3 (5). We
now present a similar series of experiments designed to determine whether the PCP-2 T3 nonresponsivity in the early neonatal rat (7, 8)
is due to insufficient levels of brain T3. Examination of brain T3
levels during development revealed that brain T3 does not reach adult
normal levels until approximately postnatal day 2 in the rat (Fig.
1).

View larger version (12K):
[in this window]
[in a new window]
|
Fig. 1.
PCP-2 expression is refractory to excess
brain T3 in the 1st week after birth. Rat brains were taken on the
indicated days after birth. mRNA levels were determined by Northern
blot analysis and are expressed as optical density units (mean ± S.E., four individual brains per point). T3 levels were determined by
radioimmunoassay and are expressed as nanograms of T3/g of brain
tissue. The difference in PCP-2 mRNA levels between euthyroid- and
T4-treated animals on postnatal day 10 is statistically significant by
analysis of variance (p < 0.01; indicated by *). No
statistically significant differences in expression were observed at
any other time points. Open triangles indicate brain T3
levels in euthyroid animals; open circles indicate PCP-2
mRNA levels in euthyroid animals; closed circles
indicate PCP-2 mRNA levels in T4-treated euthyroid animals. The
data points for days 5, 15, and 20 are graphically offset so that the
error bars can be clearly observed.
|
|
Fig. 1 further illustrates that for the first 5 days after birth,
administration of excess T3 did not result in greater PCP-2 mRNA
levels in T4-treated animals compared with euthyroid unmanipulated pups. Excess T3 did not significantly up-regulate PCP-2 expression until after postnatal day 5 when the levels of PCP-2 mRNA in the T4-treated animals began to exceed the values achieved in the euthyroid
unmanipulated pups (day 10, p < 0.01). Thus, excess T3
is capable of accelerating the rate of brain PCP-2 expression above
that produced by the euthyroid pups but not until after postnatal day
5. In conjunction with previously published results (7, 8), these data
support the view that the PCP-2 gene is refractory to thyroid hormone
from late gestation (5) until approximately 1 week after birth (Fig.
1). Of additional interest is the finding that on day 20 the levels of
PCP-2 mRNA achieved are similar for the T3-treated and euthyroid
animals, thus again demonstrating the transient effects of thyroid
hormone on PCP-2 expression (7, 8).
Developmentally Regulated Mouse Brain Nucleoproteins Bind to the
PCP-2 TRE--
We recently reported data consistent with the presence
of developmentally regulated inhibitors of thyroid hormone action in the immature Purkinje cell (9). These experiments revealed that rat
brain nuclear proteins bound to the
295/
199 region of the PCP-2
gene and that the concentration of these nucleoproteins appeared to be
present at the highest levels in fetal rat brain nuclear extracts.
In the present studies we have attempted to define more precisely the
age-related course of nuclear protein binding to the
295/
199 region
as assessed by electrophoretic mobility shift assay (Fig.
2).2
Binding activity was strongest in the late gestational fetus (E18) and
weakest in the mature adult brain (P90) (Fig. 2A). The binding activity declined with age and was reciprocally related to
PCP-2 transcriptional activity during brain development (Fig. 1) (7,
8). The fall in binding activity was not due to the presence of an
inhibitory factor in adult nuclear extracts since an equal mixture of
fetal and adult nuclear extracts still formed binding complexes on the
295/
199 region probe (Fig. 2B). The adult brain,
therefore, appears to be deficient in nucleoproteins that bind to the
295/
199 region. Additionally, adding T3 to the binding reaction did
not affect formation of the DNA-nuclear protein complexes (data not
shown).

View larger version (71K):
[in this window]
[in a new window]
|
Fig. 2.
Developmentally regulated mouse brain
nucleoproteins bind to the 295/ 199 region. A, the
295/ 199 region 32P-labeled DNA fragment was incubated
with 5 µg of nuclear extract and run on a polyacrylamide gel.
Extracts were prepared from pooled sets of brains. Three specific shift
complexes were observed. The arrowhead refers to a
nonspecific band observed in the probe alone lane. Quantitation of the
shifted bands was determined by using a PhosphorImager and the
ImageQuant computer program. Quantitation of each lane is contrasted to
the gel shift of the E18 nuclear extract as fraction of E18.
E, embryonic; P, postnatal. B, the
295/ 199 region 32P-labeled DNA fragment was incubated
with either 5 µg of E18 or P90 nuclear extract or 10 µg of E18 + E90 nuclear extract. C, the 295/ 199 region
32P-labeled DNA fragment was incubated with 5 µg of E18
nuclear extract plus equivalent molar ratios of specific competitor
DNAs. Arrows note the position of shifted bands. The three
complexes are compressed into two bands in this panel due to a shorter
time of electrophoresis.
|
|
We previously demonstrated that the A1TRE was required for fetal rat
brain nucleoprotein binding to the
295/
199 region (9). The A1TRE is
composed of three functional half-sites
(AGGCCTTCTCAGGTCAGAGACCAGGAGA; the
individual half-sites are underlined) (10). Mutation of either the 5'
or 3' half-sites diminished but did not abolish the T3 responsivity of
the A1TRE (10). Mutation of the central half-site abolished the T3
responsivity of the A1TRE (10).
Competition studies revealed that the A1TRE competed for fetal mouse
brain nucleoprotein binding to the
295/
199 region (Fig. 2C,
lanes 2-4) as previously reported (9). Mutation of either the 5'
or 3' half-sites did not abolish the ability of the A1TRE to compete
with the
295/
199 region for fetal mouse brain nucleoprotein binding
(Fig. 2C, lanes 8-13). Mutation of the middle half-site, however, did abolish the ability of the A1TRE to compete for
nucleoprotein binding (lanes 5-7). These findings suggested
that the middle half-site of the A1TRE is required for the observed
binding of mouse brain nucleoproteins to the
295/
199 region.
Synthesized TREs containing the consensus sequence AGGTCA
arranged as either a direct repeat with a 4-bp spacer (lanes 20-22) or as an inverted repeat with a 6-bp spacer (lanes
23-25) also competed for nucleoprotein binding (Fig.
2C). These findings suggest that the A1TRE binding
nucleoproteins bind to TREs that differ in both sequence, half-site
orientation, and spacing. However, the nucleoproteins do not require a
functional TRE for binding since a defective A1TRE, containing both 5'
and 3' half-site mutations, competes for nucleoprotein binding to the
295/
199 region (Fig. 2C, lanes 14-16). Finally, fetal
nucleoprotein binding to the
295/
199 region is sequence-specific
since a random sequence (lanes 17-19) and the binding site
for another transcription factor (nuclear transcription factor-I, NF-I;
lanes 26-28) do not compete.
COUP-TF Binding to the PCP-2
295/
199 Region--
The
developmentally regulated
295/
199 region-binding nucleoproteins are
present at their highest levels in the fetal and early neonatal mouse
brains (Fig. 2). During this period the PCP-2 gene is unresponsive to
T3 stimulation (5, 7, 8). The temporal association between the presence
of these proteins and the absence of T3 stimulation of PCP-2 expression
suggested that these proteins may play a role in repressing
T3-dependent transactivation of PCP-2 in the fetus and
early neonate. To test this hypothesis we attempted to identify the
295/
199 region-binding nucleoproteins. A review of the literature
raised the possibility that the orphan nuclear receptor COUP-TF could
play such a role since this nucleoprotein 1) is expressed in the
developing rat brain (26, 32, 33), 2) can bind to thyroid hormone
response elements (30), and 3) can act as a repressor of thyroid
hormone action by competing for TRE binding with the thyroid hormone
receptor (30).
We tested for the presence of COUP-TF in the
295/
199 region-mouse
brain nucleoprotein complex by supershift analysis. Three distinct
complexes are formed when nucleoproteins harvested from late
gestational (E18-E21) mouse brains are incubated with the
295/
199
region probe and subjected to an electrophoretic mobility shift assay
(Fig. 3A; lane 1). Addition of
anti-COUP-TF antibody to the reaction resulted in a supershift of two
of the three complexes (Fig. 3A, lane 2, complexes
a and c). Addition of antibody specific for the thyroid
hormone receptor isoform
1 resulted in a supershift of the third
complex (Fig. 3A, lane 3, complex b). Addition of both antibodies resulted in a supershift of all three complexes (Fig.
3A, lane 4). Addition of antibody specific for the
isoform of the thyroid hormone receptor did not result in a supershift (data not shown). These data suggest that both COUP-TF and TR
1 are
present in fetal mouse brain nuclear extracts and form specific complexes on the
295/
199 region DNA target. The anti-COUP-TF and
anti-TR
1 antibodies supershifted different complexes. This finding
suggests that COUP-TF and TR
1 probably compete for the same binding
site within the
295/
199 region.

View larger version (37K):
[in this window]
[in a new window]
|
Fig. 3.
Fetal mouse brain nucleoproteins that bind to
the 295/ 199 region include the orphan nuclear receptor COUP-TF.
A, the 295/ 199 region 32P-labeled DNA
fragment was incubated with 5 µg of E18 mouse brain nuclear extract
and run on a polyacrylamide gel. Arrowheads mark the
resulting shifted complexes and are referenced as complexes
a, b and c. Arrows mark the
positions of the complexes after supershifting. All lanes originate
from the same gel and autoradiograph. B, the 295/ 199
region 32P-labeled DNA fragment was incubated with in
vitro translated TR 1 and RXR . These translation products
bind to the A1TRE which is contained within the 295/ 199 region
(10). The arrow marks the position of the TR/RXR supershift.
C, 32P-labeled COUP-RE was incubated with
in vitro translated COUP-TFI and RXR under the conditions
described by Zou et al. (10). The arrowhead marks
the position of the COUP/RXR heterodimer. The arrow marks
the position of the COUP-TFI supershift. * refers to a nonspecific band
contributed by the rabbit reticulocyte lysate. D,
32P-labeled COUP-RE was incubated with in vitro
translated COUP-TFI and RXR . The incubation conditions are those
used by Sagami et al. (27).
|
|
Recent studies have shown that the orphan receptor ROR plays an
important role in Purkinje cell development and in the expression of
PCP-2 (34). ROR binds as a monomer to DNA sequences containing the
consensus sequence TAAGTAGGTCA (35, 36). Recently, Schrader
et al. (37) identified an ROR-binding site within the PCP-2
proximal promoter region. As the A1TRE also contains the sequence
AGGTCA, we queried whether ROR was one of the fetal mouse
brain nucleoproteins bound to the
295/
199 region. However, addition
of anti-ROR antibody did not result in a supershift, thus suggesting
that ROR is not one of the
295/
199 region-binding nucleoproteins
(Fig. 3A, lane 5).
Fig. 3B documents the capacity of anti-TR
1 antibody to
specifically supershift TR
1/RXR
heterodimers bound to the
295/
199 region. The inability of anti-COUP-TF antibody to
supershift this complex demonstrates the specificity of this antibody
(Fig. 3B). Fig. 3C documents the ability of
anti-COUP-TF antibody to supershift in vitro translated
COUP-TFI/RXR
heterodimers bound to a COUP-response element
(COUP-RE). Interestingly, we observed that formation of COUP-TFI/RXR
heterodimers versus COUP-TFI homodimers/monomers on the
COUP-RE was dependent on the assay conditions utilized (Fig. 3,
C and D).
Fetal mouse brain nucleoproteins recognized by anti-COUP-TF antibody
bind to the
295/
199 region DNA fragment. To determine whether
in vitro translated COUP-TF binds to specific sequences within the
295/
199 region, we performed a competitive mobility shift assay. In this assay we incubated labeled COUP-RE with in vitro translated COUP-TFI and various amounts of cold competitor DNA. We observed that the PCP-2 A1 TRE (
295/
268) competed with the
labeled COUP-RE for COUP-TFI binding (Fig.
4A, lanes 7-10). The
affinity, however, of COUP-TFI for the COUP-RE is significantly greater
than the affinity of COUP-TFI for the A1TRE (Fig. 4A, lanes 4-6
versus 7-10). In keeping with the reduced affinity of COUP-TFI
translation products for the A1TRE, we observed little if any binding
of COUP-TFI to the
295/
199 region DNA probe either as homo- or
heterodimers (Fig. 4B). Finally, we found that neither the
PCP-2
267/
199 region (Fig. 4A, lanes 11-14) nor a
nonspecific DNA fragment (Fig. 4A, lanes 15-18) competed
with the labeled COUP-RE for COUP-TFI binding. These findings
demonstrate that COUP-TF binds to the TRE located within the PCP-2
295/
199 region.

View larger version (65K):
[in this window]
[in a new window]
|
Fig. 4.
COUP-TFI binds to the A1TRE. A,
32P-labeled COUP-RE was incubated with in vitro
translated COUP-TFI using the incubation conditions described by Sagami
et al. (27). * refers to a nonspecific band contributed by
the rabbit reticulocyte lysate. The arrow marks the COUP-TFI
specific shift. Lane 1, probe alone; lane 2,
unprogrammed reticulocyte lysate; lane 3 in vitro translated
COUP-TF; lanes 4-18, in vitro translated COUP-TF
plus equivalent molar ratios of specific competitor DNAs. 3X
MS is a 64-bp random DNA sequence. B,
32P-labeled 295/ 199 region DNA fragment was incubated
with in vitro translated nuclear receptors. UPL
is unprogrammed rabbit reticulocyte lysate. The arrow marks
the position of the TR/RXR heterodimer. * refers to a nonspecific band
contributed by the rabbit reticulocyte lysate. Overexposure of the
autoradiograph revealed little if any COUP-TF-specific shifting.
Lanes 1-5, Zou et al. (10) gel shift conditions;
lanes 6-10, Sagami et al. (27) gel shift
conditions. Lanes 6-10 originate from the same gel and
autoradiograph.
|
|
COUP-TFI Represses T3-dependent Activation of the PCP-2
Promoter--
The gel shift data suggest a role for COUP-TF in
controlling T3 regulation of PCP-2 expression during specific stages of
brain development. To determine whether COUP-TF can specifically
repress expression of the PCP-2 promoter in vivo, we
performed transient transfection experiments. The PCP-2 reporter
construct used in these experiments contained 630 bp of PCP-2 sequence:
approximately 240 bp of regulatory sequence upstream of the start site
of transcription, the first exon, the first intron, and part of the
second exon fused to chloramphenicol acetyltransferase (CAT) as a
reporter. This construct (A1
PCP-2-CAT) contains the A1 TRE but not
the previously described
267/
199 region and has been characterized in a separate series of experiments (9). Deletion of the
267/
199 region is required for T3-dependent activation of the PCP-2
promoter (9). The reporter construct, TK28pal, was used as a control for COUP-TF-mediated repression of T3-dependent
transcriptional activation. TK28pal contains the palindromic TRE
inserted into the herpes simplex virus thymidine kinase promoter.
COUP-TF has been demonstrated to bind to the palindromic TRE with high
affinity and can block T3-dependent transactivation
mediated by this response element (30).
A1
PCP-2-CAT and TK28pal were individually co-transfected into
neuroblastoma Neuro-2a cells with a T3R
1 expression vector and
either the COUP-TFI expression vector (COUP-TFI pSG5) or the expression
vector minus the COUP-TFI coding sequence (pSG5). Transfected cells
were then cultured in the presence or absence of T3. Analysis of
reporter gene activity revealed that T3-dependent
activation of the control TK28pal was significantly inhibited by
co-transfection of the COUP-TFI expression vector (Fig.
5A). When the A1
PCP-2-CAT reporter construct was transfected into Neuro-2a cells, we found that
T3 activated reporter gene activity approximately 10-fold (Fig.
5B). Co-transfection of the COUP-TFI expression vector
COUP-TFI pSG5, however, significantly repressed (from approximately 10- to 4-fold activation) the T3-dependent activation of
A1
PCP-2-CAT (Fig. 5B). These data demonstrate that
COUP-TFI can repress T3-dependent activation of the PCP-2
promoter and are consistent with a role for COUP-TF in rendering the
PCP-2 promoter refractory to thyroid hormone in developing Purkinje
cells.

View larger version (26K):
[in this window]
[in a new window]
|
Fig. 5.
COUP-TF represses T3-dependent
transactivation of the PCP-2 promoter. A, transfection with
TK28pal. B, transfection with A1 PCP-2-CAT. The
A1 PCP-2-CAT and TK28pal constructs were co-transfected in duplicate
plates together with the indicated expression vectors into Neuro-2a
cells. The data are expressed as relative CAT activity normalized to
the CAT activity of cells co-transfected with TR 1 expression vector
and cultured in the absence of T3. The data are expressed as the
relative CAT activity for cells cultured in the presence (dark
columns) or absence (white columns) of T3. All results
represent the mean ± S.D. of three separate experiments. The
differences in fold induction are statistically significant by analysis
of variance (p < 0.001).
|
|
COUP-TF Expression in Developing Purkinje Cells--
The finding
that one of the rat brain nucleoproteins that bind to the
295/
199
region is COUP-TF supported the hypothesis that COUP-TF plays a role in
repressing T3-dependent transcriptional activation of PCP-2
during Purkinje cell development. As PCP-2 is expressed only in
cerebellar Purkinje cells, a direct test of the hypothesis required
determining whether COUP-TF is expressed in Purkinje cells and if so
whether the expression is developmentally regulated. We therefore
initiated studies to determine whether COUP-TF is expressed in Purkinje
cells in an age-dependent fashion.
Purkinje cells originate from the germinal zone of the rhombic lip and
are generated by embryonic day 15 in the rat (38). Immature Purkinje
cells migrate to the cerebellar anlage shortly before birth and form
the Purkinje cell layer. As the calbindin gene is expressed exclusively
within Purkinje cells in the cerebellum (39), immunohistochemical
detection of the calbindin protein allows identification of developing
Purkinje cells. To assess the expression of COUP-TF within developing
Purkinje cells, we harvested brains from mice of the ages indicated in
Fig. 6. The brains were processed and
sectioned for use in immunohistochemistry. Sequential sections of
tissue were individually stained with either anti-calbindin or
anti-COUP-TF antibody.

View larger version (69K):
[in this window]
[in a new window]
|
Fig. 6.
Immunohistochemical analysis of COUP-TF
expression in developing Purkinje cells. Sequential, 8-µm
sections of brains from mice of the indicated ages were incubated with
either anti-calbindin, anti-COUP-TF antisera, or nonimmune rabbit serum
followed by peroxidase-labeled second antibody. Currently, there are no anti-PCP-2
antibodies available for use in immunohistochemical studies. Incubation
with nonimmune rabbit serum resulted in a light background staining of
the entire tissue section (data not shown). Magnification of the
photomicrographs is either × 100 (100×) or × 400 (400×) as indicated. COUP-TF × 400 (COUP-TF
400×) corresponds to magnification of the area within the
white boxes of the COUP-TF × 100 (COUP-TF
100×) panels. Sections were examined from at least three
individual mouse brains at each time point. PC, Purkinje
cell layer; ML, molecular layer; EGL, external
granule cell layer; IGL, internal granule cell layer;
arrows, Purkinje cells; arrowheads, positive
nuclei in the striatum. Little COUP-TF staining was observed in the
Purkinje cells of P17, P20, P23, P26, or P30 animals (data not
shown).
|
|
We observed that COUP-TF was expressed in the nuclei of a specific
population of cells within the cerebellar anlage on embryonic day 18 (E18) fetuses (Fig. 6). Even though the immature Purkinje cell does not
yet express the calbindin marker (Fig. 6), the position of
COUP-TF-positive cells in the cerebellar anlage is consistent with the
position of migrating immature Purkinje cells (40). Immature Purkinje
cells can be directly identified by postnatal day 0 (P0) onward as
these cells have begun to express the calbindin protein (Fig. 6).
We observed that COUP-TF was expressed in the nuclei of postnatal day
0, 3, and 6 Purkinje cells (Fig. 6). In contrast, nuclear staining
markedly diminished in the Purkinje cells of P9 or older animals (Fig.
6). COUP-TF-positive nuclei were detected, however, in other brain
regions located on the same tissue sections that contained
COUP-TF-negative Purkinje cells (Fig. 6, striatum). In
keeping with previously published in situ hybridization
studies (41), cells in the molecular layer of the cerebellum appeared to express little if any COUP-TF, whereas cells found in the granule cell layer expressed COUP-TF (Fig. 6, P9 and
P12). An extranuclear ring of staining was detected around
the nuclei of some Purkinje cells from older animals (Fig. 6,
P12). This pattern of staining could either reflect
exclusion of COUP-TF from the Purkinje cell nuclei in these older
animals or could represent an experimental artifact. Such a staining
pattern was not seen, however, in sections incubated with nonimmune
serum as a negative control (data not shown). Thus, the
immunohistochemical studies revealed that COUP-TF is expressed in
Purkinje cell nuclei during the period of development when PCP-2
expression is refractory to T3 and that nuclear COUP-TF expression
diminishes at approximately the time when T3 accelerates PCP-2
expression.
 |
DISCUSSION |
Thyroid hormone facilitates normal development of the cerebellar
Purkinje cell. Thyroid hormone mediates this control in part by
modulating the transcription of specific genes expressed in the
Purkinje cell at a developmentally appropriate time. Activation of
these genes, however, is not solely dependent on the expression of T3
receptors or the attainment of critical levels of brain T3. Indeed, we
have demonstrated that these genes are refractory to T3 in the immature
Purkinje cell. Thus, the Purkinje cell appears to exert a local,
cell-specific control over thyroid hormone action during a discrete
phase of development. Release of this control during the next stage of
Purkinje cell differentiation allows thyroid hormone to regulate gene
transcription at a developmentally appropriate time.
Our findings suggest that in the immature Purkinje cell such local
control may be mediated by inhibitory transcription factors. Specifically, we have implicated the orphan nuclear receptor COUP-TF as
a potential inhibitor of thyroid hormone action in the immature Purkinje cell. The predominant patterns of COUP-TF expression within
the developing rat and mouse have prompted others to suggest a role for
COUP-TF in the hormonal control of gene expression during mammalian
development (42). Indeed, COUP-TFII has already been implicated in the
control of thyroid hormone action in developing muscle by regulating
thyroid hormone activation of specific myoD family members (43).
COUP-TFI has recently been shown to be required for appropriate
development of a subset of neurons in the peripheral nervous system
(44). Inactivation of COUP-TFI resulted in defective morphogenesis of
the glossopharyngeal ganglion and aberrant nerve projection and
arborization.
COUP-TF is widely expressed in the developing mouse brain (26, 32, 41,
45) including the cerebellar primordia (33). These patterns of
expression are consistent with an important role for COUP-TF in brain
development. There are few examples, however, of COUP-TF-regulated
neural genes. COUP-TF has been demonstrated to repress transcription of
the human transferrin gene in neuronal cells (46), block retinoic
acid-induced differentiation of neuronal teratocarcinoma PCC7 cells
(47), and regulate retinoic acid-dependent induction of the
neural specific arrestin gene (33).
In the present study we propose that COUP-TF expression in the immature
Purkinje cell renders the PCP-2 gene refractory to thyroid hormone
stimulation during the early period of Purkinje cell development. We
advance a simple model of inhibition in which COUP-TF competes with
thyroid hormone receptors for binding to the PCP-2 A1TRE. This model is
in keeping with several reports documenting a competitive mechanism for
COUP-TF-mediated repression of hormonal transcriptional activation
(reviewed by Tsai and Tsai (42)). Both COUP-TF and T3 receptors bind to
the A1TRE (Fig. 4) and are present within the immature Purkinje cell
(Fig. 6) (12). Additionally, gel shift analyses showed that anti-COUP and anti-TR
1 antibodies supershift different fetal
nucleoprotein-
295/
199 region complexes (Fig. 3). These findings
suggest that COUP-TF and TR
1 compete for binding to the same
cis-element. If so, it is likely that as the relative concentrations of
COUP-TF, T3, and thyroid hormone receptor change during development,
the outcome of competition for binding to the A1TRE will also change.
Thus, our finding that COUP-TF expression can still be detected in
Purkinje cells that have begun to express PCP-2 in a
T3-dependent fashion (Fig. 1 and Fig. 6, P7) is
consistent with the competitive hypothesis.
In vitro translated COUP-TFI binds to the A1TRE with lower
affinity than COUP-TFI to the COUP-RE (Fig. 4, A and
B). The COUP-TF found in fetal mouse brain nuclear extracts,
however, bound avidly to the
295/
199 region (Figs. 2 and 3).
Several possible explanations could account for this finding as
follows. 1) COUP-TF is modified in some fashion in vivo, and
the modified COUP-TF binds to the A1TRE with greater affinity. 2) The
fetal mouse brain nuclear protein we have identified as COUP-TF in the
gel shift and immunohistochemical experiments may only be antigenically
related to COUP-TF. The latter possibility is unlikely, however,
because the anti-COUP-TF antibody has been demonstrated by ourselves
(Fig. 3, C versus D) and others (20, 28) to recognize
COUP-TF specifically. Additionally, numerous studies have determined
that COUP-TF is expressed in fetal mouse brain cells (26, 32, 33, 45) and thus should be present in our fetal mouse brain nuclear extracts. Finally, the ability of in vitro translated COUP-TFI to bind
to the A1TRE in vitro (Fig. 3) suggests that the
295/
199
region-binding protein found in the fetal nuclear extract is indeed
COUP-TF. 3) COUP-TF heterodimerization with an unidentified fetal mouse brain nucleoprotein results in high affinity binding to the A1TRE. Such
a heterodimeric partner would probably not be TR
1 or RXR
as
neither protein enhanced COUP-TF binding to the
295/
199 region in vitro (Fig. 4B). Supporting the hypothesis of
a heterodimeric partner, however, is the finding that both the A1TRE
(
295/
268) and the
267/
199 region compete for fetal
nucleoprotein binding to the
295/
199 region in gel shift analyses
(9). It is thus possible that a nucleoprotein bound to the
267/
199
region facilitates COUP-TF binding to the A1TRE. This hypothesis is in
keeping with the T3 response silencing function we have previously
reported for the
267/
199 region (9). The presence or absence of
this putative heterodimeric partner may also influence the
T3-dependent response of PCP-2 during Purkinje cell
development.
COUP-TF may also regulate the T3-dependent transcriptional
activation of other Purkinje cell-specific genes such as calbindin and
the myoinositol-1,4,5-triphosphate receptor. Like PCP-2, both of these
genes exhibit a phasic pattern of thyroid hormone responsivity (7).
Whether COUP-TF plays a role in modulating thyroid hormone action in
other brain cells remains unclear. The ubiquitous pattern of COUP-TF
expression during brain development makes it likely, however, that
COUP-TF modulation of thyroid hormone action in the brain is not
limited to the Purkinje cell. The transient sensitivity of
T3-dependent genes to T3 during brain development contrasts sharply with the continual, nonphasic T3-dependent
regulation of lipogenic (48) or thyrotropin subunit genes (49). These genes may not be subject to the same control of thyroid hormone action
as the genes regulated by thyroid hormone during development.
The postnatal rise in brain T3 results in widespread distribution of
hormone throughout the brain. We propose, however, that the rise in
brain T3 may not be the ultimate driving force behind the initiation of
all T3-dependent developmental processes. Rather, gatekeeper transcription factors like COUP-TF may control thyroid hormone action in individual cells during discrete stages of cell development. Developmental changes in the expression of these factors
may ultimately allow initiation of the T3 response. Local control of
thyroid hormone action may thus provide cell- and stage-specific precision in the timing of thyroid hormone signaling during brain development.
 |
ACKNOWLEDGEMENTS |
We express our thanks to Dr. Ming-Jer Tsai
for the gift of the anti-COUP-TF antibody; Dr. Mitchell Lazar for the
gift of the anti-ROR antibody; Dr. Luigi Jonk for providing the
COUP-TFI expression construct; Dr. Brent Clark for assisting in our
analysis of the immunohistochemical data; and Dr. Kevin Strait for
helpful discussions. We also thank Heather Turngren for excellent
editorial support.
 |
FOOTNOTES |
*
This work was supported by National Institutes of Health
Grants DK09295 (to G. W. A.) and AM 19812 (to J. H. O.).
To whom correspondence should be addressed: Box 101 UMHC,
University of Minnesota, Minneapolis, MN 55455. Tel.: 612-624-5150; Fax: 612-626-3133; E-mail: oppen001{at}maroon.tc.umn.edu.
1
The abbreviations used are: E, embryonic; P,
postnatal; PCP-2, Purkinje cell protein-2; T3, triiodothyronine; TRE,
thryoid hormone response element; TR, thyroid hormone receptor;
COUP-TF, chicken ovalbumin upstream promoter-transcription factor; ROR; retinoic acid receptor-related orphan nuclear receptor; RXR, retinoid X
receptor; CAT, chloramphenicol acetyltransferase, COUP-RE,
COUP-response element; T4 thyroxine; bp, base pair.
2
All gel shift experiments were performed using
nuclear extracts obtained from the brains of both rats and mice.
Identical results were obtained using either rat or mouse extracts.
Only the experiments using mouse nuclear extracts are presented in this
article.
 |
REFERENCES |
-
De Long, R. G., Robbins, J., and Condliffe, P. G.
(eds)
(1989)
Iodine and the Brain, Plenum Publishing Corp., New York
-
Legrand, J.
(1986)
in
Thyroid Hormone Metabolism (Hennemann, G., ed), pp. 503-534, Marcel Dekker, Inc, New York
-
Jacobson, M.
(1991)
in
Developmental Neurobiology (Jacobson, M., ed), 3rd Ed., pp. 401-452, Plenum Publishing Corp., New York
-
Altman, J.,
and Bayer, S. A.
(1997)
in
Development of the Cerebellar System In Relation to Its Evolution, Structure, and Functions (Petralia, P., ed), pp. 379-410, CRC Press, Inc., Boca Raton, FL
-
Schwartz, H. L.,
Ross, M. E.,
and Oppenheimer, J. H.
(1997)
Endocrinology
138,
3119-3124[Abstract/Free Full Text]
-
Legrand, J.
(1967)
Arch. Anat. Microsc. Morphol. Exp.
56,
291-307[Medline]
[Order article via Infotrieve]
-
Strait, K. A.,
Zou, L.,
and Oppenheimer, J. H.
(1992)
Mol. Endocrinol.
6,
1874-1880[Abstract]
-
Sandhofer, C., Schwartz, H. L., Mariash, C. N., Forrest, D.,
and Oppenheimer, J. H. (1998) Mol. Cell. Endocrinol.,
in press
-
Anderson, G. W.,
Hagen, S. G.,
Larson, R. J.,
Strait, K. A.,
Schwartz, H. L.,
Mariash, C. N.,
and Oppenheimer, J. H.
(1997)
Mol. Cell. Endocrinol.
131,
79-87[CrossRef][Medline]
[Order article via Infotrieve]
-
Zou, L.,
Hagen, S. G.,
Strait, K. A.,
and Oppenheimer, J. H.
(1994)
J. Biol. Chem.
269,
13346-13352[Abstract/Free Full Text]
-
Hagen, S. G.,
Larson, R. J.,
Strait, K. A.,
and Oppenheimer, J. H.
(1996)
J. Mol. Neurosci.
7,
245-255[Medline]
[Order article via Infotrieve]
-
Bradley, D. J.,
Towle, H. C.,
and Young, W. S.
(1992)
J. Neurosci.
12,
2288-2302[Abstract]
-
Ruiz de Ona, C.,
Obregon, M. J.,
Escobar del Rey, F.,
and Morreale de Escobar, G.
(1988)
Pediatr. Res.
24,
588-594[Medline]
[Order article via Infotrieve]
-
Strait, K. A.,
Schwartz, H. L.,
Perez-Castillo, A.,
and Oppenheimer, J. H.
(1990)
J. Biol. Chem.
265,
10514-10521[Abstract/Free Full Text]
-
Forrest, D.,
Hanebuth, E.,
Smeyne, R. J.,
Everds, N.,
Stewart, C. L.,
Wehner, J. M.,
and Curran, T.
(1996)
EMBO J.
15,
3006-3015[Medline]
[Order article via Infotrieve]
-
Morreale de Escobar, G.,
Pastor, R.,
Obregon, M.,
and Escobar del Rey, F.
(1985)
Endocrinology
117,
1890-1900[Abstract]
-
Ortiz, M. A.,
Peidrafita, F. J.,
Pfahl, M.,
and Maki, R.
(1995)
Mol. Endocrinol.
9,
1679-1691[Abstract]
-
Lucas, P. C.,
Foreman, B. M.,
Samuels, H. H.,
and Granner, D. K.
(1991)
Mol. Cell. Biol.
11,
5164-5170[Abstract/Free Full Text]
-
Yen, P. M.,
Liu, Y.,
Sugawara, A.,
and Chin, W. W.
(1996)
J. Biol. Chem.
271,
10910-10916[Abstract/Free Full Text]
-
Cooney, A. J.,
Leng, X.,
Tsai, S. Y.,
O'Malley, B. W.,
and Tsai, M.-J.
(1993)
J. Biol. Chem.
268,
4152-4160[Abstract/Free Full Text]
-
Calvo, R.,
Obregon, M.,
Ruiz de Ona, C.,
Escobar del Ray, F.,
and Morreale de Escobar, G.
(1990)
J. Clin. Invest.
86,
889-899
-
Surks, M.,
Schadlow, A.,
and Oppenheimer, J.
(1972)
J. Clin. Invest.
51,
3104-3113
-
Chomcznski, P.,
and Sacchi, N.
(1987)
Anal. Biochem.
162,
156-159[Medline]
[Order article via Infotrieve]
-
Correa-Rotter, R.,
Mariash, C. N.,
and Rosenberg, M. E.
(1992)
BioTechniques
12,
154-158[Medline]
[Order article via Infotrieve]
-
Bradford, M. M.
(1976)
Anal. Biochem.
72,
248-254[CrossRef][Medline]
[Order article via Infotrieve]
-
Jonk, L. J. C.,
deJonge, M. E. J.,
Pals, C. E. G. M.,
Wissink, S.,
Vervaart, J. M. A.,
Schoorlemmer, J.,
and Kruijer, W.
(1994)
Mech. Dev.
47,
81-97[CrossRef][Medline]
[Order article via Infotrieve]
-
Sagami, I.,
Tsai, S. Y.,
Wang, H.,
Tsai, M. J.,
and O'Malley, B. W.
(1986)
Mol. Cell. Biol.
6,
4259-4267[Abstract/Free Full Text]
-
Wang, L.-H.,
Tsai, S. Y.,
Cook, R. G.,
Beattie, W. G.,
Tsai, M.-J.,
and O'Malley, B. W.
(1989)
Nature
340,
163-166[CrossRef][Medline]
[Order article via Infotrieve]
-
Falcone, M.,
Miyamoto, T.,
Fierro-Renoy, F.,
Macchia, E.,
and DeGroot, L. J.
(1992)
Endocrinology
131,
2419-2429[Abstract]
-
Cooney, A. J.,
Tsai, S. Y.,
O'Malley, B. W.,
and Tsai, M.-J.
(1992)
Mol. Cell. Biol.
12,
4153-4163[Abstract/Free Full Text]
-
Tacha, D. E.,
and Chen, T.
(1994)
Histotechnology
17,
365
-
Qui, Y.,
Cooney, A. J.,
Kuratani, S.,
DeMayo, F. J.,
Tsai, S. Y.,
and Tsai, M.-J.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
4451-4455[Abstract/Free Full Text]
-
Lu, X. P.,
Salbert, G.,
and Pfahl, M.
(1994)
Mol. Endocrinol.
8,
1774-1788[Abstract]
-
Hamilton, B. A.,
Frankel, W. N.,
Kerrebrock, A. W.,
Hawkins, T. L.,
FitzHugh, W.,
Kusami, K.,
Russell, L. B.,
Mueller, K. L.,
van Berkel, V.,
Birren, B. W.,
Kruglyak, L.,
and Lander, E. S.
(1996)
Nature
379,
736-738[CrossRef][Medline]
[Order article via Infotrieve]
-
Carlberg, C.,
Hooft can Huijsduijnen, R.,
Staple, J.,
DeLamarter, J. F.,
and Becker-Andre, M.
(1994)
Mol. Endocrinol.
8,
757-770[Abstract]
-
Giguere, V.,
Tini, M.,
Flock, G.,
Ong, E.,
Evans, R. M.,
and Otulakowski, G.
(1994)
Genes Dev.
8,
538-553[Abstract/Free Full Text]
-
Schrader, M.,
Danielsson, C.,
Wiesenberg, I.,
and Carlberg, C.
(1996)
J. Biol. Chem.
271,
19732-19736[Abstract/Free Full Text]
-
Altman, J.,
and Bayer, S. A.
(1997)
in
Development of the Cerebellar System In Relation to Its Evolution, Structure, and Functions (Petralia, P., ed), pp. 99-106, CRC Press, Inc., Boca Raton, FL
-
Nordquist, D. T.,
Kozak, C. A.,
and Orr, H. T.
(1988)
J. Neurosci.
8,
4780-4789[Abstract]
-
Altman, J.,
and Bayer, S. A.
(1997)
in
Development of the Cerebellar System In Relation to Its Evolution, Structure, and Functions (Petralia, P., ed), pp. 173-203, CRC Press, Inc., Boca Raton, FL
-
da Silva, S. L.,
Cox, J. J.,
Jonk, L. J. C.,
Kruijer, W.,
and Burbach, J. P. H.
(1995)
Mol. Brain Res.
30,
131-136[Medline]
[Order article via Infotrieve]
-
Tsai, S. Y.,
and Tsai, M.-J.
(1997)
Endocr. Rev.
18,
229-240[Abstract/Free Full Text]
-
Muscat, G. E.,
Rea, S.,
and Downes, M.
(1995)
Nucleic Acids Res.
23,
1311-1318[Abstract/Free Full Text]
-
Qui, Y.,
Pereira, F. A.,
DeMayo, F. J.,
Lydon, J. P.,
Tsai, S. Y.,
and Tsai, M.-J.
(1997)
Genes Dev.
11,
1925-1937[Abstract/Free Full Text]
-
Brubaker, K.,
McMillan, M.,
Neuman, T.,
and Nornes, H. O.
(1996)
Dev. Brain Res.
93,
198-202[CrossRef][Medline]
[Order article via Infotrieve]
-
Sawaya, B. E.,
and Schaeffer, E.
(1995)
Nucleic Acids Res.
23,
2206-2211[Abstract/Free Full Text]
-
Neuman, K.,
Soosaar, A.,
Nornes, H. O.,
and Neuman, T.
(1995)
J. Neurosci. Res.
41,
39-48[CrossRef][Medline]
[Order article via Infotrieve]
-
Mariash, C. N.,
Kaiser, F.,
and Oppenheimer, J. H.
(1980)
Endocrinology
106,
22-27[Medline]
[Order article via Infotrieve]
-
Shupnik, M. A.,
Ridgway, E. C.,
and Chin, W. W.
(1989)
Endocr. Rev.
10,
459-475[Medline]
[Order article via Infotrieve]
Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore